- Home
- ABL vs ARCT Comparison
ABL vs ARCT Comparison
Compare ABL & ARCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ABL
- ARCT
- Stock Information
- Founded
- ABL 2004
- ARCT 2013
- Country
- ABL United States
- ARCT United States
- Employees
- ABL N/A
- ARCT N/A
- Industry
- ABL Investment Managers
- ARCT Biotechnology: Pharmaceutical Preparations
- Sector
- ABL Finance
- ARCT Health Care
- Exchange
- ABL Nasdaq
- ARCT Nasdaq
- Market Cap
- ABL 640.3M
- ARCT 526.5M
- IPO Year
- ABL N/A
- ARCT N/A
- Fundamental
- Price
- ABL $6.46
- ARCT $7.88
- Analyst Decision
- ABL Strong Buy
- ARCT Buy
- Analyst Count
- ABL 2
- ARCT 11
- Target Price
- ABL $12.00
- ARCT $38.67
- AVG Volume (30 Days)
- ABL 917.9K
- ARCT 2.2M
- Earning Date
- ABL 11-06-2025
- ARCT 11-10-2025
- Dividend Yield
- ABL N/A
- ARCT N/A
- EPS Growth
- ABL N/A
- ARCT N/A
- EPS
- ABL 0.12
- ARCT N/A
- Revenue
- ABL $196,551,131.00
- ARCT $97,601,000.00
- Revenue This Year
- ABL $81.75
- ARCT N/A
- Revenue Next Year
- ABL $20.16
- ARCT $26.81
- P/E Ratio
- ABL $54.56
- ARCT N/A
- Revenue Growth
- ABL 91.93
- ARCT N/A
- 52 Week Low
- ABL $4.60
- ARCT $7.77
- 52 Week High
- ABL $9.61
- ARCT $24.17
- Technical
- Relative Strength Index (RSI)
- ABL 60.07
- ARCT 28.14
- Support Level
- ABL $5.00
- ARCT $7.93
- Resistance Level
- ABL $7.18
- ARCT $9.29
- Average True Range (ATR)
- ABL 0.40
- ARCT 0.62
- MACD
- ABL 0.18
- ARCT -0.06
- Stochastic Oscillator
- ABL 66.28
- ARCT 0.27
About ABL Abacus Life Inc.
Abacus Global Management Inc is a financial services company specializing in alternative asset management, data-driven wealth solutions, technology innovations, and institutional services. The Company organizes its business into five reportable segments Active Management, Originations, Asset Management, Portfolio Servicing, and Technology Services. Its operations are confined to the United States.
About ARCT Arcturus Therapeutics Holdings Inc.
Arcturus Therapeutics Holdings Inc is an RNA medicines company focused on opportunities in rare diseases with a current focus on liver and respiratory diseases. It operates in one business segment, which includes all activities related to the discovery, development and commercialization of messenger RNA medicines. The company's pipeline includes LUNAR-OTC, LUNAR-CF, LUNAR-FLU, and LUNAR-COV19.